Biomednewsbreaks Biofrontera Inc. (NASDAQ: BFRI) Announces $4.5M Registered Direct

(MENAFN- Investor Brand Network) Biofrontera (NASDAQ: BFRI) , a biopharmaceutical company specializing in the commercialization of dermatologic products, recently entered into a securities purchase agreement with a certain institutional investor, pursuant to which the company agreed to issue and sell to the investor an aggregate of 1,205,000 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase an aggregate of up to 1,807,000 shares of common stock, at an exercise price of $3.55 per share of common stock. According to the announcement, the warrants are exercisable immediately upon issuance and will expire five years following the date of issuance. Biofrontera also agreed to adjust the strike price of 385,236 outstanding warrants held by the investor to $3.55. Roth Capital Partners is acting as the exclusive placement agent for the offering. The company intends to use the net proceeds for working capital and general corporate purposes.

To view the full press release, visit

About Biofrontera Inc.

Biofrontera is a U.S.-based biopharmaceutical company commercializing a portfolio of products for the treatment of dermatologic conditions with a focus on photodynamic therapy (“PDT”) and topical antibiotics. The company's licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection.

About BioMedWire

(“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed)and Life Sciences sectors. It is one of 60+ brands within
Dynamic Brand Portfolio
that delivers :
(1) access to a vast network of wire solutions via
to efficiently and effectively reach a myriad of target markets, demographics and diverse industries ;
(2) article and
editorial syndication to 5,000+ outlets ;
(3) enhanced
press release enhancement
to ensure maximum impact ;
social media distribution
via IBN to millions of social media followers ;
and (5) a full array of tailored
corporate communications solutions . With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today's market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire,“Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published:

San Francisco, CA

415.949.5050 Office

BioMedWire is powered by


Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.